Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Multicenter, Open-label, Dose-escalation Trial of MBC-11, an Etidronate-ara-C Conjugate in Patients With Malignant Tumors With Cancer-induced Bone Disease (CIBD)

NCT02673060 is registered in ClinicalTrials.gov with Osteros Biomedica Ltd as lead sponsor.

NCT NCT02673060
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02673060 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Multicenter, Open-label, Dose-escalation Trial of MBC-11, an Etidronate-ara-C Conjugate in Patients With Malignant Tumors With Cancer-induced Bone Disease (CIBD)
Lead sponsor
Osteros Biomedica Ltd
Phase
Phase 1
Overall status
Completed
Start date
July 31, 2014
Completion date
December 31, 2015
Enrollment
16 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

bone metastasis